Abstract |
The combinations of tricyclodecan-9-yl-xanthogenate ( D 609) with undecanoic acid (C11) and D 609 with myristic acid (C14) were tested in 3 rodent tumor models in vivo. D 609 in combination with C11 or C14 did not show antitumoral efficacy in 3-Lewis lung carcinoma (3-LL) growing in syngeneic C57BL6-mice (primary tumor and metastasis) or in WEHI-3B myelomonocytic leukemia growing in Balb/c mice, when given in a dose range lower than the lethal dose for 10% of the treated animals (LD10). In L 1210 mouse lymphoid leukemia growing in CD2F1 mice the combination of D 609/C11 given intraperitoneally in a concentration of 100 mg/kg for more than 1 day effected a significant difference in the survival curves between the control and therapeutic groups in 1 out of 2 experiments. In conclusion, the treatment schedules of D 609/C11 or D 609/C14 used in this study has not revealed significant therapeutic effects in mouse tumors or leukemias in vivo.
|
Authors | H D Schick, S Danhauser-Riedl, E Amtmann, R Busch, A Reichert, G Steinhauser, J Rastetter, G Sauer, W E Berdel |
Journal | Cancer letters
(Cancer Lett)
Vol. 46
Issue 2
Pg. 149-52
(Jul 15 1989)
ISSN: 0304-3835 [Print] Ireland |
PMID | 2752384
(Publication Type: Journal Article)
|
Chemical References |
- Bridged-Ring Compounds
- Fatty Acids
- Myristic Acids
- Norbornanes
- Thiocarbamates
- Thiones
- undecanoic acid
- tricyclodecane-9-yl-xanthogenate
|
Topics |
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bridged-Ring Compounds
(administration & dosage)
- Fatty Acids
(administration & dosage)
- Female
- Leukemia L1210
(drug therapy)
- Leukemia, Experimental
(drug therapy)
- Lung Neoplasms
(drug therapy, secondary)
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Myristic Acids
(administration & dosage)
- Neoplasms, Experimental
(drug therapy)
- Norbornanes
- Thiocarbamates
- Thiones
(administration & dosage)
|